PBA
XENE icon

Paradigm Biocapital Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,043,280
Closed -$79.7M – 43
2024
Q2 		$79.7M Sell
2,043,280
-441,594
-18% -$17.7M 3.05% 13
2024
Q1 		$107M Buy
2,484,874
+357,474
+17% +$16.4M 3.77% 10
2023
Q4 		$98M Buy
2,127,400
+635,565
+43% +$22.5M 4.59% 10
2023
Q3 		$51M Buy
1,491,835
+502,508
+51% +$18.8M 3.46% 15
2023
Q2 		$38.1M Buy
989,327
+338,259
+52% +$13.4M 2.94% 16
2023
Q1 		$23.3M Buy
+651,068
New +$24.1M 2.21% 19

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Paradigm Biocapital Advisors's XENE Position: Q3 2024 in Review

Paradigm Biocapital Advisors sold out of Xenon Pharmaceuticals (XENE) in Q3 2024, closing a stake of 2,043,280 shares — an estimated $79.7M sold.

Paradigm Biocapital Advisors first reported a position in XENE in Q1 2023 and held it in 6 quarters. The position peaked at $107M in Q1 2024. 203 funds tracked by Wall St. Rank hold XENE as of Q3 2024.

  • Paradigm Biocapital Advisors reported no remaining Xenon Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 2,043,280 Xenon Pharmaceuticals shares in Q3 2024, an estimated $79.7M.
  • Paradigm Biocapital Advisors first reported a position in Xenon Pharmaceuticals in Q1 2023 and held it in 6 quarters.
  • Paradigm Biocapital Advisors's Xenon Pharmaceuticals position peaked at $107M in Q1 2024.
  • 203 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.